Back to Search
Start Over
FDA Grants Breakthrough Therapy Designation for Genzyme's Olipudase Alfa
- Source :
- Business Wire. June 4, 2015
- Publication Year :
- 2015
-
Abstract
- Investigational enzyme replacement therapy designed to treat the nonneurological manifestations of ASMD which characterize Niemann-Pick disease type B CAMBRIDGE, Mass. -- Genzyme, a Sanofi company, announced today that the U.S. [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.416367190